Pfizer's Candidate for Oral Antiviral Treatment of COVID-19
PAXLOVID™ (PF-07321332; ritonavir) to significantly reduce the risk of hospitalization or death
Pfizer and BioNTech Collaborate with Biovac
The South African biopharmaceutical company will manufacture and distribute COVID-19 vaccine doses within Africa
Vaccine Candidate More Than 90% Effective in Preventing COVID-19
Pfizer and BioNTech announce vaccine candidate achieved success in first interim analysis from Phase 3 study
Pfizer and BioNTech Agree Vaccine Supply with the UK
30 million doses of mRNA-based vaccine candidate against SARS-CoV-2 expected to be delivered in 2020/2021, subject to regulatory approval or authorization
Can the Pharmaceutical Industry Restore its Broken Image?
John LaMattina, former President, Pfizer Global R&D, discusses his book on how and why the pharma industry is devalued and distrusted
New Computational Method for Safer Leads
Elegant way to limit the number of biochemical experiments to predict the toxicity of a drug candidate won Molecular Informatics Best Paper Award
Dispelling the Myths About Pharma R&D
John L. LaMattina talks about his book Drug Truths and the myths about pharma R&D
Pfizer Announce R&D Cuts
R&D plant at Sandwich, UK, will close with the loss of 2,400 jobs
Pfizer Launches Academic Network
Network with around eight partners from the US, Europe, Asia/Australia focussing on developing biologics-based drugs planned